Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. Issue 17 (25th June 2013)

• Record Type: Journal Article
• Authors: Diletti, Roberto; Garcia-Garcia, Hector M; Bourantas, Christos V; van Geuns, Robert Jan; Van Mieghem, Nicolas M; Vranckx, Pascal; Zhang, Yao-Jun; Farooq, Vasim; Iqbal, Javaid; Wykrzykowska, Joanna J; de Vries, Ton; Swart, Michael; Teunissen, Yvonne; Negoita, Manuela; van Leeuwen, Frank; Silber, Sigmund; Windecker, Stephan; Serruys, Patrick W
• Is Part Of: Heart. Volume 99:Issue 17(2013)
• Page Start: 1267
• Page End: 1274
• Publication Date: 2013-06-25
• Subjects: Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2013-303778
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Objective: We investigated clinical outcomes after treatment of coronary bifurcation lesions with second generation drug eluting stents (DES). Design: Post hoc analysis of a randomised, multicentre, non-inferiority trial. Setting: Multicentre study. Patients: All comers study with minimal exclusion criteria. Interventions: Patients were treated with either zotarolimus or everolimus eluting stents. The patient population was divided according to treatment of bifurcation or non-bifurcation lesions and clinical outcomes were compared between groups. Main outcomes measures: Clinical outcomes within 2-year follow-up. Results: A total of 2265 patients were included in the present analysis. Two-year follow-up data were available in 2223 patients: 1838 patients in the non-bifurcation group and 385 patients in the bifurcation group. At 2-year follow-up the bifurcation and the non-bifurcation lesion groups showed no significant differences in terms of cardiac death (2.3 vs 2.1, p=0.273), target lesion failure (9.7% vs 13.8%, p=0.255), major adverse cardiac events (11.5% vs 15.1%, p=0.305), target lesion revascularisation (4.7% vs 6.0%, p=0.569), and definite or probable stent thrombosis (1.6% vs 1.8%, p=0.419). Conclusions: The use of second generation DES for the treatment of coronary bifurcation lesions was associated with similar long term mortality and clinical outcomes compared with non-bifurcation lesions.